New diabetes pill shows Real-World promise in japan
NCT ID NCT04878393
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 31 times
Summary
This study followed 650 adults with type 2 diabetes in Japan who were prescribed oral semaglutide (Rybelsus) by their doctors. The goal was to see how well the medication lowers blood sugar and what side effects occur in everyday use. Participants took the pill once daily and completed a questionnaire during regular clinic visits over 8-10 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Master Centre for Japan
Tokyo, 1000005, Japan
Conditions
Explore the condition pages connected to this study.